Harmony Biosciences (HRMY) vs Immunome (IMNM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Harmony Biosciences (HRMY) has outperformed Immunome (IMNM) over the past year, gaining 49.1% versus a gain of 37.8%. Over five years, IMNM leads with a +9.7% price change compared with +0.5% for HRMY. Harmony Biosciences is the larger company by market cap ($2.31 billion vs $2.28 billion), about 1.0 times the size.
Harmony Biosciences converts more of its revenue into profit, with a net margin of 18.3% versus -3060.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HRMY | IMNM |
|---|---|---|
| Share price | $39.60 | $19.31 |
| Market cap | $2.31B | $2.28B |
| 1-day change | +0.66% | +1.13% |
| YTD return | +5.83% | -10.10% |
| 1-year return | +49.10% | +37.83% |
| 5-year return | +0.51% | +9.65% |
| P/E ratio (TTM) | 12.77 | — |
| Forward P/E | 5.65 | — |
| EPS (TTM) | $3.10 | $-2.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $868.45M | $6.94M |
| Revenue growth (YoY) | +21.51% | -23.23% |
| Net income (latest FY) | $158.69M | $-212.39M |
| Gross margin | 77.16% | — |
| Operating margin | 24.00% | -3228.83% |
| Net margin | 18.27% | -3059.99% |
| 52-week high | $43.49 | $30.06 |
| 52-week low | $25.52 | $13.49 |
| Distance from 52-week high | -8.94% | -35.76% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +20.30% | +82.29% |
| Average volume | 892.55K | 1.20M |
| Shares outstanding | 58.24M | 118.00M |
| Employees | 293 | 247 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HRMY has outperformed IMNM by 11.3 percentage points over the past year.
- Harmony Biosciences is more profitable, keeping 18.3 cents of every revenue dollar as net income versus -3060.0 cents for Immunome.
- Harmony Biosciences grew revenue faster in its latest fiscal year (+21.51% vs -23.23%).
- The two companies sit in different sectors: Harmony Biosciences in Health Care and Immunome in Healthcare.
About Harmony Biosciences
HRMY stock →Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees
About Immunome
IMNM stock →Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.
Healthcare · Biotechnology · 247 employees
HRMY vs IMNM FAQ
Which is bigger, Harmony Biosciences or Immunome?
Harmony Biosciences (HRMY) is larger, with a market capitalization of $2.31B compared with $2.28B for Immunome (IMNM).
Which stock has performed better over the past year, HRMY or IMNM?
HRMY returned +49.10% over the past 12 months, compared with +37.83% for IMNM (price return, excluding dividends). Past performance does not predict future results.
Are Harmony Biosciences and Immunome in the same industry?
No. Harmony Biosciences is in the Health Care sector, while Immunome is in Healthcare.